We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology
Due to their unrivalled tumor specificity, our antibodies can be developed into different mechanisms of action. Together with our partners, we strive to combine our antibodies with complementary technologies and to fully exploit their capabilities to develop novel first-in-class therapies for cancer patients with unmet medical needs. The foundation of all of our successful partnerships is a shared understanding of our values and vision. We are committed to our partners and our open and collaborative spirit fosters successful partnerships.
Daiichi Sankyo: Based on a worldwide licensing agreement signed in 2018, Daiichi Sankyo develops an antibody drug conjugate (ADC) by combining Daiichi Sankyo’s proprietary ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody GT-00A.
ONK Therapeutics: Glycotope’s antibody GT-00A will be integrated into ONK’s pre-clinical program ONKT103, for solid tumors. ONK is set to bring the natural benefits of NK cells over T cells to bear on TA-MUC1, in a tumor-specific fashion, while boosting efficacy and countering resistance through the use of their TRAIL variant targeting DR5.
Medizinische Hochschule Hannover: The MHH and Glycotope have joined forces to research the suitability of carbohydrate antigens for CAR-T development.
Charité Comprehensive Cancer Center: The partnership between Glycotope and the Charité Comprehensive Cancer Center has existed for many years. During this time, a wide variety of projects have been carried out jointly to advance cancer treatment.
Fraunhofer Institute for Cell Therapy and Immunology: Various research projects.